Symptoms reported by COVID-19 cases at baseline and at follow-up. by Spela Kokelj (8356644)

Subjects:

Training impact on electrical properties of P3 lumbar MNs. Rin: input resistance. Rheobase: lowest intensity of current injected in MNs to elicit an action potential (AP). AP threshold: voltage measured at the foot of the AP. AP amplitude: measured between the resting membrane potential and the AP peak. AP half width: time spent by the potential > 50% of the AP maximum amplitude. AP rise time: time spent by the potential between 10% and 90% of the AP maximum amplitude. AP half decay time: time spent by the potential between the AP maximum amplitude and the 50% decreasing amplitude. ADP: after-depolarization potential. All values are means ± SEM. The number of MNs recorded is indicated between brackets. ns: no significantly different.... by Camille Quilgars (21156495)

“…All values are means ± SEM. The number of MNs recorded is indicated between brackets. ns: no significantly different. …”

<b> </b> Spatial memory assessment in Morris water maze test. 5A: Effect of different treatments on time spent in the target zone. Alcl3 significantly decreased the time spent in the target zone with respect to the saline-treated group (p < 0.01).... by Atefeh Sadeghi (21253051)

“…<p><b> </b> Spatial memory assessment in Morris water maze test. 5A: Effect of different treatments on time spent in the target zone. Alcl3 significantly decreased the time spent in the target zone with respect to the saline-treated group (p < 0.01). …”

Effects of BM-MSCs on ROS generation in DCS rats. by Chen Lu (135200)

Subjects:

Pretreatment of BM-MSCs attenuates DCS induced lung inflammation. by Chen Lu (135200)

Subjects:

Isotype control overlays. by Chen Lu (135200)

Subjects:

Original uncropped blot. by Chen Lu (135200)

Subjects:

Characterization of BM-MSC. by Chen Lu (135200)

Subjects:

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Subjects:

Utilization of anticoagulants at eight hospitals from 2019 to 2023. by Wei Luo (80175)

Subjects:

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The demographical and clinical characteristics of subjects at baseline. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Identification of BM-MSCs. by Chen Lu (135200)

Subjects:

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Inpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Indications for warfarin prescription in outpatients and inpatients in 2023. by Wei Luo (80175)

Subjects:

Time to stabilization in the mediolateral direction. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Outpatient utilization of anticoagulants from 2019 to 2023. by Wei Luo (80175)

Subjects:

Participant’s data including characteristics and primary outcome measurement. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Effects of BM-MSCs on different types of lung cell death in different group. by Chen Lu (135200)

Subjects: